Noema Pharma plc (NASDAQ:NOEMW – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 883 shares, a decline of 65.1% from the September 15th total of 2,531 shares. Based on an average daily volume of 9,040 shares, the short-interest ratio is presently 0.1 days.
Noema Pharma Stock Performance
NASDAQ NOEMW traded up $0.00 during mid-day trading on Wednesday, reaching $0.10. 425 shares of the stock were exchanged, compared to its average volume of 19,861. The business’s 50 day moving average is $0.14 and its 200-day moving average is $0.12. Noema Pharma has a 1 year low of $0.07 and a 1 year high of $0.24.
Noema Pharma’s pipeline has included investigational compounds targeting neurological conditions such as fragile X syndrome and tuberous sclerosis complex. Its programs are designed to modulate biological pathways associated with abnormal brain signaling, with development stages and indications subject to change as clinical studies progress.
The company is headquartered in Switzerland and operates internationally through research, clinical development and collaborations with healthcare and biotechnology organizations.
See Also
- Five stocks we like better than Noema Pharma
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Noema Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Noema Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
